» BioStock Investor Pitch: Stayble Therapeutics expands operations
» Further steps in Aptahem's Phase I study
» Stimulants and groundbreaking research pave the way for new orphan drugs
» Ultimovacs on the way to Phase II readout
» Progress for SynAct Pharma in 2022 – more milestones await
Read BioStock's newsletter for v.8 here.
Do not miss BioStock Investor Pitch w/ Stayble Therapeutics vd Andreas Gerward. See the presentation here or via the banner below.
Morning news
PolarCool signs 2-year contract with Swiss hockey club SC Bern - for PolarCap. Read more.
BioArctics application for marketing authorisation for lecanemab receives priority review by the National Medicines and Healthcare Products Regulatory Agency (NMPA). Read moreThe company also announces that Anders Martin-Lof became the new CFO. Read more.
Elekta receives FDA 510(k) clearance for advanced motion control in radiation therapy with Elekta Unity MR-Linac. Read more.
Lipigon decides on a rights issue of units of approximately SEK 35,4 million. Read more.
Today the subscription period begins in VibroSense Dynamics Rights issue of B shares. Read more.
AegirBios UK facility is assessed according to ISO 13485. Read more.
The Analysis Guide publishes analyses of Bone support (Read more) and Cantargia (read more).
Yuko Nagasawa is the new CEO of Getinge Japan. Read more.
Redeye has updated its analysis of SUFFER. Read more.
Milestone for stem cell-based therapy for Parkinson's – first patient transplanted at Skåne University Hospital with a product developed by researchers at Lunds university. Read more.
Reports:
Chordate Medical Coegin Pharma DanCann Pharma Dicot Eurocine Vaccines FluoGuide Glycorex Inhalation Sciences Invent Medic Lifecare Lipigon Nanoform Nexstim Nordic Nanovector Nykode Therapeutics Orion Group QuiaPEG RaySearch Laboratories RLS Global Vicore Pharma
Invitation to report presentation:
Insider trading
Changes in equity and number of votes:
On March 16th, the BioStock the first digital BioStock Investor Meeting of the year. Representatives of leading life science companies in several therapeutic areas will have the opportunity to present themselves to investors and potential partners.
The event will be broadcast online at BioStocks website and YouTube channel.
News since Monday lunch
Chordate Medicals Italian distributor Ve.Di.Se. Hospital SPA. has installed KOS treatment for chronic rhinitis at eleven clinics in the country. Read more.
Promore Pharma has reached the Clean File milestone in its Phase II clinical study with enserepeptide. Read more.
PainDrainer has carried out a new share issue of SEK 10 million. Read more.
Corline Biomedical extends distribution agreement with agent in the USA. Read more. Penser has done an analysis of the company (Read more).
Calmarks vd Camilla Arneving has been interviewed by Direkt. Read more.
Redeye has commented Alzecures Q4 report. Read more.
Penser has done analyses on Idogen (Read more), Vivesto.(Read more) and Devotion (Read more).
Analyst Group has commented Fluicells Q4 report. Read more.
InDex Pharmaceuticals participates in ECCO Congress 2023. Read more.
iZafe Group has signed an exclusive agreement in the Netherlands. Read more.
Pharma Equity Group has called an investor meeting. Read more.
Bonzun is starting a partnership with Sturebadet Medical Clinic. Read more.
This morning's price development
Winner: Calmark 15,5%, Invent Medic 13,5%, Ortoma 13,0%, Odinwell 12,3%, Carbiotix 8,8%
Förlorare: Lipigon -24,1%, Idogen -17,1%, Ellen -10,3%, PharmacLundensis -9,0%, PolarColl -8,7%
Index: OMXS30 2218 -0,74%, Healthcare -0,67%